First of all, thank you, Ms. McPherson, for the question and for moving this motion. I think it's a really important one and I'm very glad to be here on this issue.
With regard to COVAX and bilateral deals, when COVAX was created last June, it was intended to serve as a stopgap to ensure that vaccines went to the developing world. Its objective was to provide vaccines for 20% of the populations of countries that joined COVAX. COVAX is on track to deliver this by the end of 2021, which was its objective from the beginning, and in fact it looks as though it will be able to deliver up to 30%.
When it was conceived, it was precisely to deal with this issue, and it locked in that supply for COVAX member countries right from the beginning and recognized that—